The in vitro effect of recombinant erythropoietin on cisdiamminodichloroplatinum-induced inhibition of murine erythroid stem cells.
An in vitro study was carried out to evaluate the possible protective effect of recombinant human erythropoietin (rhEpo) on cisplatin (CDDP)-induced inhibition of erythroid colony growth. CDDP at the dose of 0.4 mg/ml caused a 72-75% inhibition of erythroid stem cell growth in plasma clots. In the short-term assay rhEpo was not able to protect normal murine erythroid stem cells from the inhibitory effect of CDDP at any of the tested concentrations. In long-term bone marrow cultures, although the kinetics of cellular populations in suspensions and of erythroid stem cells were similar in both controls and CDDP-treated cultures, both cellularity and erythroid stem cells levels were much lower in CDDP-treated flasks than in control ones regardless of the addition of rhEpo. These results indicate that rhEpo is not able to prevent of ameliorate erythroid stem cell inhibition due to a possible toxic effect of CDDP, at least in vitro.
Gebbia
V
V
Section of Medical Oncology, University, of Palermo, Italy.
Valenza
R
R
Rausa
L
L
D000818:Animals; D001854:Bone Marrow Cells; D002448:Cell Adhesion / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D002945:Cisplatin / Q000494:pharmacology*; D003114:Colony-Forming Units Assay; D004921:Erythropoietin / Q000494:pharmacology*; D005260:Female; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000187:drug effects; D007700:Kinetics; D051379:Mice; D008815:Mice, Inbred Strains; D011994:Recombinant Proteins / Q000494:pharmacology
D011994:Recombinant Proteins; D004921:Erythropoietin; D002945:Cisplatin